SCHEMBL5578447

SCHEMBL5578447

C=CCN1CCC2(CC1)CN(C(=O)c1cccc(F)c1F)c1c2ccc(C)c1C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.36
ATM Q13315 1/20 0.35
SIGMAR1 Q99720 1/20 0.34
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
DRD2 P14416 1/20 0.33
OPRD1 P41143 1/20 0.31
OPRK1 P41145 1/20 0.31
MAPK10 P53779 2/20 0.31
MAPK8 P45983 1/20 0.31
HRH2 P25021 1/20 0.31
HRH1 P35367 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
RORC P51449 1/20 0.30
BCHE P06276 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578898 0.91 SIGMAR1 (0.36) SIGMAR1HDAC1HDAC6OPRD1OPRK1
SCHEMBL5579040 0.88 HPGD (0.38) HPGDATMSIGMAR1DRD2OPRD1
SCHEMBL5578907 0.86 HPGD (0.35) HPGDATMSIGMAR1HDAC1HDAC6
SCHEMBL5616163 0.85 DRD2 (0.39) SIGMAR1DRD2HRH2HRH1
SCHEMBL5578569 0.84 OPRD1 (0.34) HPGDATMSIGMAR1OPRD1HRH2
SCHEMBL5578767 0.82 ATM (0.45) HPGDATMSIGMAR1HDAC1HDAC6
SCHEMBL5781194 0.81 EPHX2 (0.36) HPGDATMOPRD1HRH2HRH1
SCHEMBL4890379 0.80 P2RX7 (0.39) HPGDATMSIGMAR1HDAC1HDAC6
SCHEMBL5579307 0.78 ATM (0.36) HPGDATMSIGMAR1HDAC1HDAC6
SCHEMBL5579092 0.78 MAPK8 (0.36) SIGMAR1OPRD1OPRK1MAPK10MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US claimed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL HPGD 219/4885ATM 2441/4885SIGMAR1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.